At 11.9% CAGR, South & Central America Bioproduction Market is Projected to be Worth US$ 1,965.21 Million by 2030, says Business Market Insights

According to Business Market Insights' research, the South & Central America bioproduction market was valued at US$ 799.67 million in 2022 and is expected to reach US$ 1,965.21 million by 2030, registering a CAGR of 11.9% from 2022 to 2030. Shift toward automated cell therapy manufacturing and increasing prevalence of chronic diseases are among the critical factors attributed to drive the South & Central America bioproduction market growth.

Automation can deliver many benefits for cell therapy developers, including reduced risk of contamination, improved consistency, and reduced cost of production. Many companies have offered devices to enable automation, such as the Lonza Cocoon and the CliniMACS Prodigy system from Miltenyi are designed to enable the automation of most sequential unit operations for a CAR-T process within a single system. A rising number of cell therapies have shifted the production of cell therapy products from a small volume to a large volume worldwide. In addition, the evolution of cell therapy, from an academic and clinical setting to mass production and commercialization, is increasing the demand for automation in manufacturing. Increasing research activities in cell therapies have led to a rise in demand for advanced manufacturing solutions. In view of this, many players are offering products to meet the digital needs of academic researchers and large biotechnology companies. For instance, in May 2019, GE Healthcare launched the Chronicle web application to support the complete cell therapy workflow. Chronicle automation software is a good manufacturing practice (GMP)-compliant digital solution designed to optimize complex cell therapy process development and manufacturing.

Companies are also entering into strategic and technological developments for automation in cell therapy. For instance, in July 2020, Thermo Fisher Scientific Inc. and Lyell Immunopharma partnered to develop and manufacture processes to design effective cell therapies for cancer patients. Under this partnership, the companies aim to improve the fitness of T-cells and support the development of an integrated current good manufacturing practice (cGMP) compliant platform (system and software) along with reagents, consumables, and instruments. Thus, the increasing adoption of automation among cell therapy manufacturers is anticipated to drive the market.

On the contrary, high cost of cell therapy and biosimilar manufacturing hampers the growth of South & Central America bioproduction market.

Based on product, the South & Central America bioproduction market is segmented into biologics and biosimilars, vaccines, cell and gene therapies, nucleic acid therapeutics, and others. The biologics and biosimilars segment held 38.2% South & Central America bioproduction market share in 2022, amassing US$ 305.71 million. It is projected to garner US$ 703.92 million by 2030 to register 11.0% CAGR during 2022-2030.

In terms of application, the South & Central America bioproduction market is segmented into rheumatoid arthritis, hematological disorders, cancer, diabetes, cardiovascular diseases, and others. The cancer segment held 36.4% share of South & Central America bioproduction market in 2022, amassing US$ 290.99 million. It is anticipated to garner US$ 744.84 million by 2030 to expand at 12.5% CAGR during 2022-2030.

By equipment, the South & Central America bioproduction market is divided into upstream equipment, downstream equipment, bioreactors, and consumables and accessories. The consumables and accessories segment held 39.9% share of South & Central America bioproduction market in 2022, amassing US$ 319.44 million. It is projected to garner US$ 829.10 million by 2030 to expand at 12.7% CAGR from 2022 to 2030.

In terms of end user, the South & Central America bioproduction market is categorized into biopharmaceutical companies, contract manufacturing organizations, and others. The biopharmaceutical companies segment held 51.1% share of South & Central America bioproduction market in 2022, amassing US$ 408.83 million. It is projected to garner US$ 993.48 million by 2030 to expand at 11.7% CAGR from 2022 to 2030.

Based on country, the South & Central America bioproduction market is categorized into Brazil, Argentina, and the Rest of South & Central America. Our regional analysis states that Brazil captured 66.5% share of South & Central America bioproduction market in 2022. It was assessed at US$ 531.38 million in 2022 and is likely to hit US$ 1,331.04 million by 2030, registering a CAGR of 12.2% during 2022-2030.

Key players operating in the South & Central America bioproduction market are Lonza Group AG, Danaher Corp, Sartorius AG, Thermo Fisher Scientific Inc, Merck KGaA, F. Hoffmann-La Roche Ltd, and Bio-Rad Laboratories Inc, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com